A new analysis of pooled data from prior PROVENT Therapy studies (abstract 0570) by Philip Westbrook, MD, Emeritus Professor of Medicine at UCLA and Ventus Medical’s Chief Medical Officer, and colleagues, showed success rates and a significant change in Apnea-Hypopnea Index (AHI) in 58 patients that demonstrate the viability of PROVENT Therapy via expiratory resistive loading in the treatment of OSA.³

“These success rates are comparable to alternative therapies, such as mandibular advancement devices and surgical approaches, and PROVENT had fewer adverse events,” explained Westbrook. “Given PROVENT Therapy is much easier to try than these other therapies, it could be an early consideration for the treatment of OSA.”

Results demonstrated that PROVENT Therapy reduced AHI from 26.6±24.8 to 13.7±20.1, a 49% reduction (P<0.001). During the treatment night, 72% of subjects met either the AHI<10 or AHI improved by at least 50% criteria; 36% met the success criteria of AHI<5; 59% met AHI<10; and 66% had an AHI<50% of their baseline value.  Further, 50% of subjects met both the AHI<10 and AHI improved by at least 50% criteria.³

3. Westbrook P, Doshi R, Loomas B. Success Rates of Nasal Expiratory Positive Airway Pressure (nEPAP) Via Expiratory Resistive Load for the Treatment of Obstructive Sleep Apnea, June 9, 2009, poster presentation at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies. Abstract 0570.